One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Diabetes increases morbidity and mortality in cystic fibrosis (CF) patients, but several studies indicate that also prediabetic status may have a potential impact on both nutrition and lung function. OBJECTIVE: To evaluate the effect of glargine on the clinical course in CF patients with early glucose derangements. METHODS: CF population was screened for glucose tolerance. CF patients with age >10 yr were screened with fasting hyperglycemia (FH). CF patients with age >10 yr without FH and those with age <10 yr with occasional FH were evaluated for glucose abnormalities on the basis of oral glucose tolerance test and/or continuous glucose monitoring system. All CF patients with glucose derangements were enrolled in an open clinical trial with glargine. Body mass index (BMI) z-score, forced expiratory volume in the first second (FEV(1)), number of acute pulmonary exacerbations and hemoglobin A1c, were as outcome measures at baseline and after 1 yr of treatment. RESULTS: After 12 months of therapy, BMI z-score improved only in patients with baseline BMI z-score less than -1 (p = 0.017). An 8.8% increase in FEV(1) (p = 0.01) and 42% decrease in the number of pulmonary exacerbations (p = 0.003) were found in the whole group compared with previous 12 months of therapy. CONCLUSION: Glargine could represent an innovative strategy to prevent lung disease progression in CF patients with early glucose derangements. Larger controlled trials are needed to better clarify the effects of insulin on clinical status in CF patients with early glucose derangements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1768 · Cited by 726
Villella, V. R., Esposito, S., Bruscia, E. M., Maiuri, M. C., Raia, V., Kroemer, G., & Maiuri, L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00001 · Cited by 389
Self-citationEpidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis–Related Diabetes
Moran, A., Becker, D., Casella, S. J., Gottlieb, P. A., Kirkman, M. S., Marshall, B. C., Slovis, B., & the CFRD Consensus Conference Committee (2010) · Diabetes Care · doi:10.2337/dc10-1279 · Cited by 258
Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia
Moran, A., Pekow, P., Grover, P., Zorn, M., Slovis, B., Pilewski, J., Tullis, E., Liou, T. G., Allen, H., & the Cystic Fibrosis Related Diabetes Therapy Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0585 · Cited by 240
“Recently, small pilot studies have suggested that low-dose insulin glargine may improve weight or pulmonary function in patients with cystic fibrosis who have abnormal glucose tolerance without causing significant hypoglycemia (19,20).”
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171
Metadata
- Authors
- Mozzillo, E., Franzese, A., Valerio, G., Sepe, A., De Simone, I., Mazzarella, G., Ferri, P., & Raia, V.
- Venue
- Pediatric Diabetes
- Publisher
- Hindawi Limited
- Published
- 2009-05
- Volume
- 10
- Issue
- 3
- Pages
- 162-167
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W2133708874
- Cited by
- 108
- References
- 0
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. https://app.cochat.ai/papers/10.1111/j.1399-5448.2008.00451.x
- The paper
- Mozzillo, E., Franzese, A., Valerio, G., Sepe, A., De Simone, I., Mazzarella, G., Ferri, P., & Raia, V. (2009). One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatric Diabetes. https://doi.org/10.1111/j.1399-5448.2008.00451.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.